1-3 of 3
Luz Hammershaimb
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Deirdre O'Mahony, John C. Morris, Maryalice Stetler-Stevenson, Helen Matthews, Margaret R. Brown, Thomas Fleisher, Stefania Pittaluga, Mark Raffeld, Paul S. Albert, Dirk Reitsma, Karen Kaucic, Luz Hammershaimb, Thomas A. Waldmann, John E. Janik
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2514–2522.
https://doi.org/10.1158/1078-0432.CCR-08-1254
Published: 01 April 2009
View article titled, EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Open the PDF for EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7851–7860.
https://doi.org/10.1158/1078-0432.CCR-05-0262
Published: 08 November 2005
View article titled, Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Open the PDF for Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion in another window
Journal Articles

α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel

René Bruno, Robert Olivares, Jocelyne Berille, Philip Chaikin, Nicole Vivier, Luz Hammershaimb, Gerald R. Rhodes, James R. Rigas
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 1077–1082.
Published: 01 March 2003
View article titled, α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel
Open the PDF for α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel in another window